Mammography Market: Current Analysis and Forecast (2022-2028)

Mammography is a non-invasive medical diagnostic procedure that is used for the screening of breast tissues for cancerous cells. A mammography exam, or mammogram, uses analog, digital, computer-aided detection, and tomosynthesis systems to highlight small tumors, cysts, and other irregularities in the breasts. The mammography market is expected to grow tremendously in the coming years due to the surge in the incidences of breast cancer and rising awareness among the population regarding the benefits of early diagnosis of cancer. According to the American Cancer Society, in 2021, 281,550 new cases of breast cancer are estimated to be diagnosed, and around 49,290 related deaths are expected to occur in the U.S. alone. As per the World Health Organization (WHO), in 2021, breast cancer is the most common type of cancer at a global level, with new cases surpassing 2.3 million.

The Mammography Market is expected to grow at a steady rate of around 8% owing to technological advancements and an increase in investment by pharmaceutical giants. The key players are rapidly launching novel products, which are also having a positive impact on market growth. For instance, in October 2022, PDC launched Comfort Cushion Mammography Pad for use by mammography providers, including hospitals and breast and women's health centers. The cushy pad is applied by mammography technicians to the receptor plate of the mammography machine to reduce patient discomfort during compression. Moreover, in December 2021, GE advanced a mammographic platform that offered 3D technology utilizing the same low radiation that traditional 2D technology does.

Based on product, the market is segmented into film screen systems, digital systems, analog systems, and 3D systems. The digital systems held a dominant share of the market in 2020 due to their superior depiction of low-contrast objects, wider dynamic change, and enhanced diagnostic quality of images, especially when examining denser breasts. Moreover, a wide range of product availability is also boosting the demand for digital systems. For instance, in August 2021, FUJIFILM Medical Systems Inc. launched ScreenPoint Medical's, FDA cleared Transpara powered by Fusion artificial intelligence (AI) for 2D and 3D mammography in the U.S. In addition, in April 2021, Fujifilm GmbH launched the "Harmony" version of its Amulet Innovality mammography system in Germany. AMULET Innovality is a Full Field Digital Mammography (FFDM) equipped with Fujifilm's unique and innovative technologies that achieve optimum image quality at a very low patient dose.

On the basis of the technology outlook, the market is categorized into breast tomosynthesis, CAD mammography, and digital mammography. The breast tomosynthesis segment is anticipated to witness a high CAGR during the forecast period. The technique utilizes a high-resolution limited angle tomography technology that uses X-rays to create a 3-dimensional image of the breast. It helps in the identification of breast cancer at an early stage, and also reduces the risk of false-positive readings. Thus, these factors are propelling the segmental growth during the forecast period.

Based on modality, the market is bifurcated into portable and non-portable. Portable mammography held a significant share of the market in 2020 as these are designed to be utilized in wide range of settings, including primary care offices, hospitals, and clinics. These offer the convenience of on-site breast screening for patients who may not have easy access to traditional mammography systems. This mammography is getting popular in developed countries as patients and providers alike seek out more convenient and affordable care options.

On the basis of end-use, the market is segmented into hospitals, speciality clinics, diagnostic centers, ambulatory surgical centers, and educational & research institutes. In 2020, hospitals held a dominant share in the market. The presence of mammography facilities in hospitals has a positive effect on various factors, such as duration of hospital stay, total healthcare cost, quality of care, and availability of emergency care. For instance, in September 2019, Parkside Hospital in Wimbledon installed a 3Dmammography system from Hologic that enables high-resolution breast tomosynthesis.

For a better understanding of the market adoption of mammography, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period attributed to the rise in the incidences of breast cancer, high research and development activities, and novel product launches. According to the GLOBOCAN 2020 database, around 92,024 new breast cancer cases were diagnosed that accounting for 8.9% of all cancer cases in Japan. This significant disease prevalence is set to proliferate business growth in the near future. Moreover, rising government initiatives to increase awareness among individuals will also have a positive impact on the market's growth. For instance, the Breast Health Global Initiative (BHGI), an alliance of public & private organizations issues supportive guidelines for early detection and therapeutics of breast cancer in low- and middle-income countries in Asia to improve awareness and clinical outcomes. Furthermore, some countries in the region such as South Korea, Japan, Singapore, and Taiwan among others have started population-based screening campaigns.

Some of the major players operating in the market include: Hologic, Inc.; CANON MEDICAL SYSTEMS CORPORATION; Siemens Healthcare GmbH; Koninklijke Philips NV; FUJIFILM Holdings Corporation; GE HealthCare; Metaltronica S.p.A; PLANMED OY; Carestream Health; and Analogic Corporation.